Skip to content

Depression: all studies

Page 770 of 1,034: studies 7,691 to 7,700 of 10,336, newest first. Back to the depression overview

Research

N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine

Human Psychopharmacology: Clinical and Experimental February 17, 2022 Edward James, Joachim Keppler, Ben Sessa et al. 41 citations

Abstract Objective Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of...

'Mindfulness Living with Insomnia': an mHealth intervention for individuals with insomnia in China: a study protocol of a randomised controlled trial.

BMJ Open February 15, 2022 Chen Pan, Bingyu Tie, Weichao Yuwen et al.

Introduction: Insomnia has a remarkably negative effect on the work, quality of life and psychosomatic health of individuals, and imposes a substantial economic burden on society. Mindfulness-based interventions (MBIs) have proven beneficial in the treatment of insomnia. However, the effect of mobile or online-based (mHealth) MBIs requires further verification. This study will evaluate the...

Real-world patient characteristics, treatment patterns, efficacy and safety of intramuscular ketamine treatment: a retrospective cohort study

Research Square February 14, 2022 Sachin Ahuja, Madeline Brendle, Leo Smart et al. 2 citations preprint

Abstract Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment, and an evaluation of the real-world efficacy and safety of long-term...

Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review

Cells February 12, 2022 Alina Wilkowska, Mariusz S. Wiglusz, Katarzyna Jakuszkowiak‐wojten et al. 23 citations

BACKGROUND AND OBJECTIVES: Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression. Although many studies have been published, there is still not enough data on the effect of ketamine in combination with other medications. Particularly interesting is the combination of ketamine and lamotrigine, and its potential...

DOI: 10.3390/cells11040645 (opens in new tab) Ketamine Lamotrigine Psychopharmacology Epilepsy

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

Journal of Neurochemistry February 12, 2022 Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo et al. 108 citations

Abstract 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that...

DOI: 10.1111/jnc.15587 (opens in new tab) Anxiety Agonist Depression economics Pharmacology +1

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

Journal of Clinical Medicine February 11, 2022 Chia‐ling Yu, Chih-Sung Liang, Fu-Chi Yang et al. 37 citations

We examined the cardiovascular safety, acceptability, and trajectory of the antidepressant effects of psilocybin after single- or two-dose administration. Four major electronic databases were systematically searched. Data were pooled using a multivariate random-effects meta-analysis. Primary outcomes were changes in depressive symptoms. Secondary outcomes were cardiovascular safety and...

DOI: 10.3390/jcm11040938 (opens in new tab) Psilocybin Placebo Meta-analysis Discontinuation +5

The role of yoga in inflammatory markers

Brain, Behavior, & Immunity - Health February 10, 2022 Carolina Estevao

Yoga is an ancient system for integrating the mind, body, and spirit. In the hatha yoga ashtanga tradition (the eight limb Patanjali Yoga), three of the limbs are meditation, breathwork (pranayama) and physical postures (asana), which are widely practised in yoga classes. The benefits of yoga for mental and physical health are rooted in the practice's origins: in yoga, stress is said to be the...

Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson's disease.

BMC Complementary Medicine and Therapies February 7, 2022 Jojo Yan Yan Kwok, Jung Jae Lee, Edmond Pui Hang Choi et al.

Importance: Patients with long-term neurological conditions, such as Parkinson's disease (PD), are particularly vulnerable to the public health measures taken to combat the COVID-19 pandemic. The inaccessibility of center-based rehabilitation further aggravated their motor dysfunctions as well as mental distress, leading to exacerbation of motor and non-motor symptoms, high healthcare...

DOI: 10.1186/s12906-022-03519-y (opens in new tab) Full text (opens in new tab) Mindfulness Humans Parkinson disease Gait disorders, neurologic +17

Hallucinogen chemistry guides antidepressant drug discovery

C&EN Global Enterprise February 7, 2022 Bethany Halford

Scientists have long sought the secrets of the 5-HT 2A serotonin receptor—a central nervous system receptor that binds hallucinogenic compounds, including LSD and psilocybin. Many hope to discover why these molecules cause hallucinations when they bind to 5-HT 2A while other compounds that bind to the receptor, including serotonin, do not. LSD and psilocybin have been shown to treat mood...

DOI: 10.1021/cen-10005-leadcon (opens in new tab) Hallucinogen Antidepressant Drug discovery Pharmacology

Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD)

ACS Omega February 7, 2022 Robert B. Kargbo, Alexander M. Sherwood, Poncho Meisenheimer et al. 5 citations

Psilocybin, a serotonergic agonist, was granted a "breakthrough therapy" status by the Food and Drug Administration for clinical trials involving major depressive disorder and treatment-resistant depression. The direct phosphorylation of psilocin to psilocybin that uses a fast crystallization associated with a kinetically controlled process resulted in a smaller particle size distribution....

DOI: 10.1021/acsomega.1c06708 (opens in new tab) Psilocybin Nucleation Metastability Recrystallization geology +7